Pioneers of Industrial Biochemistry
Ushering in solutions for a new life sciences enabled-era by leveraging vast amounts of information for optimized biomolecules to improve healthLearn about our technology →
Ushering in a new era empowered by biology to create breakthrough products to treat disease in an unprecedented manner by combining mankind’s understanding of genomics, immunology and advanced engineering.
WOBURN, Mass., February 01, 2017 – Abpro, a leading therapeutic antibody company targeting human disease and at the forefront of synthetic biology, today announced the expansion of its senior leadership team with Adam Mostafa as Chief Financial Officer
MedImmune, the global biologics research and development arm of AstraZeneca, and Abpro, an integrated life sciences company at the forefront of synthetic biology, today announced they have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).
Abpro, an integrated life science company at the forefront of synthetic biology, today announced co-development agreements with Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH), two of the country’s leading academic medical centers
Abpro is a Massachusetts based biotechnology company. We are pioneers of industrial biochemistry and our mission is to bring innovation to the life sciences industry and ultimately improve living health. Through technology and automation, our DiversImmune™ discovery platform has streamlined all aspects of the process to deliver antibodies at industry leading speeds against previously difficult targets. Our products and discovery services are used by leading academic labs and companies around the world for research purposes, such as diagnostics and therapeutics.